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Characterization of Pathogenic Mutations in 21-
Hydroxylase Gene of Pakistani Patients with
Congenital Adrenal Hyperplasia and their
Family Members - a Preliminary Report
A. H. Khan,M. I. Nasir,T. Moatter  ( Department of Pathology, The Aga Khan University Hospital,
Karachi. ) 
Abstract 
Objective: To characterize specific mutations within the 21-hydroxylase gene (CYP21-B) using
ARMS-PCR assay in patients with congenital adrenal hyperplasia (CAH) and to compare it with that
reported in other populations.
Subjects and Methods: Five families, having an index case with CAH diagnosed on the basis of
clinical and biochemical findings volunteered to give blood samples for analysis. A strategy, based on
ARMS-PCR (Amplified Refractory Mutation System) was employed for the detection of mutations in
21 -hydroxylase gene. The products of ARMS-PCR were resolved on agarose gels and the PCR
products were visualized over ultra violet illumination.
Results: Twenty-six specimens were analyzed for common point mutations in the 21-hydroxlase genes
at the nucleotide positions 659, 1004 and 1688. Seven samples belonged to index cases with CAH. Of
these 7, the assigned sex was male in 5 and female in 2 cases. However, genotypic sex was 3 males and
4 females. The mean age was 8 months in 5 cases while the median 17-OH Progesterone levels was
273.2 ng/ml. Vomiting, precocious puberty and ambiguous genitalia were the presenting features in 2, 1
and 4 cases respectively. Analysis for mutation at 659, 100 and 1688 was performed on 7 index cases
and the family members of 5 index cases. The mutation analysis for the family members of index case
6 and 7 was not performed due to non-availability of their blood specimens. Index case No. 1, 4 and 7
showed homozygosity for splice mutations at nucleotide position 659, intron 2 with a sequence change
of A to G, while the index case No. 2 and 6 showed heterozygosity for the same mutation. No mutation
was found at 659, 1004 or 1688 in index case No. 3 and 4 at the analyzed nucleotide position.
Nineteen family members of Case Nos. 1-5 were also analyzed for the same mutations. (Family No. 1,
2, 3, 4 and 5 included 3, 2, 7, 4 and 5 members respectively). These included 8 males and 11 females.
All were asymptomatic. Both the parents of index case I and 4 were heterozygous at 659 while the
father of index case No. 2 was heterozygous at 659 and mother was normal.
Conclusion: Our results demonstrated the A to G transition at nucleotide 659 causing aberrant splicing,
reported for some other populations as the most commonly identified point mutations. All cases were
appropriately assigned to paternal or maternal chromosomes (JPMA 52:287;2002).
Abbreviations:  CAH = Congenital adrenal hyperplasia; 17-OHP = 1 7-Hydroxy Progesterone; SW =
Salt
Wasting; SV = Simple Virilizing; NC = Non-Classical; CYP21 B or CYP21A2 = 21-hydroxylase
gene; CYP21 P or
CYP21P = 21-hydroxylase pseudogene; ARMS = Amplified Refractory Mutation System.
Introduction 
The newborn with abnormal development of genitalia presents a difficult diagnostic and treatment
challenge. It is important that a defmitive diagnosis be determined as quickly as possible so that an
appropriate treatment plan can be established to minimize medical, psychological and social
complications. Ever since corticosteroids substitution therapy became available and it’s beneficial
effects on Congenital Adrenal Hyperplasia (CAH) were discovered, the outcome of CAH has been a
target ot mterest. Keports on long-term prognosis have mostly been focused upon growth, fertility and
also during recent years on bone mineral density1-3.
Steroid 21-hydroxylase deficiency is the major cause of CAH, which exists in three forms: Salt
wasting, Simple Virilizing and nonclassical, which reflect different degrees of clinical severity of the
disease4,5. All three forms of CAH are inherited as recessive disorders and the gene defectscausing the
enzyme deficiencies are all believed to be found in the 21-hydroxylase gene known as CYP21, located
on the short arm of chromosome Two highly homologous and closely linked steroid 21-hydroxylase
genes are found in humans; the CYP21 gene (CYP21B or CYP21A2) is active, while the CYP21P
(CYP21A) gene is a pseudogene and is inactive due to small insertions, deletions and point mutations
in the gene4-7. CYP21 gene deletion and gene conversion to the inactive CYP2IP form are common in
CAH subjects, but less than 35% of all CYP21 gene mutations fall into these categories. Likewise
amino acid substitutions have been described in CYP21; however these mutations account for only a
relatively small percentage of CAH cases8-10.
In general, a close correlation exists between genotype and phenotype, with certain mutations
associated closely with salt wasting, others with simple virilizing and others with non-classical
disease8. However, phenotypes have been reported that were more or less severely affected than would
have been predicted by genotype. The most common point mutation in CYP21B is the intron 2 splice
mutation at nucleotide Variable clinical manifestations have been reported in patients who have this
mutation. Leakiness of splice mutations has been postulated as one source of the genetic variability. A
small amount of mRNA is spliced normally, resulting in the synthesis of a small amount of functioning
enzyme and sufficient enzyme activity to ameliorate the severity of the phenotype4,5.
So far no data exists in our population about the incidence of this disease though a number of cases
have been presented at the cytogenetics division of the Department of Pathology with ambiguous
genitalia and with clinical and biochemical fmdings of CAH. This study is an attempt to find mutations
in the CYP21 gene of patients with CAH and to characterize the specific mutations in our population.
The initial database produced from this study will be utilized for prospective studies in future.
Subjects and Methods 
Subjects
Five families, each having an index case with CAH diagnosed on clinical and biochemical grounds
volunteered to give blood samples for analysis. Blood samples were also collected from two other
index cases, but the samples from their family members were not collected. The index case No.1 was
phenotypically and genotypically a male child, who presented at 5 months of age with severe vomiting,
diarrhea and failure to thrive and very high 17-OHP levels (273.2 ng/ml). Index case No.2 presented
with genital ambiguity including clitoromegaly and persistence of urogenital sinus at 40 days of life.
The child was assigned a male sex however, karyotyping showed 46XX chromosomes and uterus and
ovaries were seen on ultrasound examination. The 17-OHP level was >400 ng/ml. Index case No.3 and
6 presented with features of virilization. Index cases No. 5 and 7 also presented with ambiguous
genitalia with kaiyotyping assigned appropriately to sex.
Methods
A strategy, based on the use of ARMS-PCR was employed for detection of mutation as previously
described by Wedell and Luthman9. A preamplification step was performed to amplify specifically the
21B sequence in preference to the 21A. A second round of ARMS was then performed to identify
mutations in using the amplified 21B sequence as a template.
Protocol for detection of mutation
The 21B gene was amplified in two fragments using standard PCR reactions. Fragment A was used for
analyzing point mutation at position 659 whereas fragment B was tested for mutations at 1004 and
1688 bp. Briefly, 500 ng of DNA was amplified in the presence of primers P1 and P48 (100 ng each)
for fragment A and primers P4 and P55 (100 ng each for fragment B in 1 X PCR buffer, 0.2 mM
deoxyribonucleotides, 1.5 mM MgCi2, 1.25 U Taq polymerase (Advanced Biotechnologies, USA) in a
fmal volume of 25 1. The amplication was performed in a thermal cycler model 9700 (Perkin Elmer,
USA) using the following cycling conditions; 93°C for 1 min, 54°C for and at 72°C for 1 min for a
total of 20 cycles. The primer sequences of P1, P48, P4 and P55 were described previously by Wedell
and Luthman9. The products of this reaction were diluted to seed the second round of mutation specific
PCR using primer sequences described previously9.The products of the second round of amplification
were resolved on agarose gels (3% for the 659 mutation and 1% for the others) and bands were
visualized using ethidium bromide.
Results 
Twenty-six specimens were analyzed for common point mutations in the 2l-hydroxlase genes at
nucleotide positions 659, 1004 and 1688 (Table 1).
Of the total, 7 samples belonged to index cases with congenital adrenal hyperplasia. Of these 7, the
assigned sex was male in 5 cases and female in 2 cases. However, genotypic sex was 3 males and 4
females. The mean age was 8 months in 5 cases and the median 17-OHP level found in these cases was
273.2 ng/ml. Two cases presented with vomiting, 1 with precocious puberty and 4 with ambiguous
genitalia.
Mutations in CAH subjects
Analysis for 659, 1004 and 1688 was performed on 7 index cases (Table 2).
Index case No. 1, 4 and 7 showed homozygosity for splice mutations at nucleotide position 659, intron
2 with a sequence change of A or C to G, while the index case No. 2 and 6 showed heterozygosity for
the same mutation. No mutation was found in nucleotide position 659, 1004, 1688 in index case No. 3
and 4.
Mutations in Family members
A total of 19 family members of Case Nos. 1-5 were also analyzed for the same mutations. (Family No.
1,2, 3, 4 and 5 included 3, 2, 7, 4, and 5 members respectively). These included 8 males and 11
females. All were asymptomatic. The mutation analysis for the family members of index case 6 and 7
was not performed due to non-availability of their blood specimens.
Mutations in Parents
Both the parents of index case I were heterozygous
at 659 (father CG, mother AG). However they showed normal genotypes at nucleotide position 1004
and 1688. The parents of index case 4 also showed heterozygosity at 659 (father AG, mother AG).
The father of index case 2 was heterozygous at 659 (AG) and mother was normal. The mutational
analysis at 1004 and 1688 demonstrated normal genotypes.
The parents of index case 3 and 5 did not show any of the analyzed mutation. However instances of
PCR failure were also noted for index case 3.
Mutations in Unaffected sibling pairs
The brother of index case 1 was heterozygous for 659 (AG). No mutation was identified at the
examined nucleotide positions in the sisters of index case 4 and the unaffected siblings of index case 3
and 5
Discussion 
Our results demonstrated A to G transition at nucleotide 659 causing aberrant splicing, reported for
some other populations as the most commonly identified point mutations11-15. All cases were
appropriately assigned to paternal or maternal chromosome.
At least 16 different mutations have been described within the 21B gene. Most have been derived from
the 21A pseudogene. However, novel mutation will always be a possibility4,16. Consequently, it will
not be feasible to screen exhaustively for all mutations in a service environment. It has been reported
that by screening for the common point mutations at positions 659, 1004, 1688 and 2113 in addition to
the short-range mapping strategy described for identifying deletions and gene conversion events,
majority of pathogenic mutations are identified4. Causative mutations can be identified in 95% of
patients using this system. The point mutation at 2113 in our cases could not be performed due to
technical reasons.
Given the diversity of clinical presentation and the relationship of severe disease with specific
genotypes it is important to clearly characterize the CAH genotypes among Asian population17. Also
given the high rates of consanguinity in Pakistan, genotyping of chorionic villous sampling may be the
only practical option for antenatal diagnosis. It is important and interesting to investigate in this area,
which has been suggested to be the most common autosomal recessive disorder in humans, with
prevalence in Ashkenazi Jews of 3.7% and in a diverse Caucasian population of 0.l%5. Studies have
indicated a variable incidence of the disease in children with early onset of pubic hair as well as in
adolescents and adult females who have hirsutism5. Moreover prenatal diagnosis is also possible by use
of a number of modalities like amniotic fluid hormonal levels, HLA typing of fetal cells obtained by
amniocentesis.
If a couple has had a child with CAH, only 1in 4 subsequent pregnancies will be affected, and only 1 in
8 will be an affected female. Because androgens, irrespective of source, masculinize the genitalia
between 6 and 14 weeks of gestation, treatment with dexamethasone must be instituted as early as
possible in pregnancy. Thus, these groups have advocated that all fetuses that are potentially at risk,
both affected and unaffected, should receive dexamethasone from 4 to 6 weeks gestation until about 12
weeks, when chorionic villous biopsy and DNA analysis can disclose the fetal sex and presence of
P450c21 gene defects. If chorionic villous biopsy is unavailable, treatment is continued until 15 to 18
weeks, when amniocentesis can be performed for DNA analysis. At this point treatment is continued
only in affected homozygous fetuses, i.e., only in 1 of 8 pregnancies initially treated. The ethics of
needlessly subjecting 7 of 8 fetuses not at risk for CAH to an experimental therapy with unknown long-
term consequences remain unresolved and the long term safety and outcomes have not been
established. Prenatal diagnosis reduces the risk of treatment to the mother if the fetus is a male or
unaffected female18,19.
Because of the wide range of mutations in the 21- hydroxylase gene, unraveling the genotype in CAH
among Asians is a daunting task. There is a clear need to setup national or regional gene banks and it
may be cost effective to pool resources to do so.
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